Obesity and diabetes

被引：80
作者：
Boutari, Chrysoula [1 ,2 ]
DeMarsilis, Antea [2 ]
Mantzoros, Christos S. [2 ,3 ,4 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Med Sch, Dept Internal Med, Thessaloniki, Greece
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA
[3] Boston VA Healthcare Syst, Dept Med, Boston, MA USA
[4] Beth Israel Deaconess Med Ctr, 330 Brookline Ave,SL418, Boston, MA 02215 USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2023年 / 202卷
关键词：
Obesity; Diabetes mellitus; Cardiovascular disease; Nonalcoholic fatty liver disease; Antidiabetics; T2DM management; LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; FREE FATTY-ACIDS; WEIGHT-LOSS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; BARIATRIC SURGERY; DOUBLE-BLIND; BODY-WEIGHT;
D O I：
10.1016/j.diabres.2023.110773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Obesity, which has currently reached pandemic dimensions, is usually accompanied by diabetes mellitus type 2 (T2DM). These two conditions share common pathophysiological mechanisms. Adipose tissue secretes cytokines which are involved in inflammation and various endocrine functions. As for T2DM, it is characterized also by inflammation, mitochondrial dysfunction, and hyperinsulinemia. These conditions occur also in other diseases related to obesity and T2DM, like cardiovascular disease (CVD) and nonalcoholic fatty liver disease (NAFLD). Thus, management of obesity-related complications with lifestyle modification, anti-obesity drugs, and bariatric surgery, all contribute to improvement in any of these conditions. This review provides an overview of the literature addressing the association between obesity and T2DM, briefly discussing the pathophysiological mechanisms linking these conditions and outlining the management approach at the overlap of obesity and T2DM.
引用
收藏
页数：11
相关论文
共 175 条
[1]   Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation [J].
Alessi, MC ;
Bastelica, D ;
Mavri, A ;
Morange, P ;
Berthet, B ;
Grino, M ;
Juhan-Vague, I .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (07) :1262-1268
[2]   Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis [J].
Ali, Mahmoud M. ;
Hafez, Ahmed ;
Abdelgalil, Mahmoud Shaban ;
Hasan, Mohammed Tarek ;
El-Ghannam, Mohammed Magdy ;
Ghogar, Osama M. ;
Elrashedy, Asmaa Ahmed ;
Abd-ElGawad, Mohamed .
BMC ENDOCRINE DISORDERS, 2022, 22 (01)
[3]   GIP-Dependent Expression of Hypothalamic Genes [J].
Ambati, S. ;
Duan, J. ;
Hartzell, D. L. ;
Choi, Y. -H. ;
Della-Fera, M. A. ;
Baile, C. A. .
PHYSIOLOGICAL RESEARCH, 2011, 60 (06) :941-950
[4]   Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy [J].
Angelidi, Angeliki M. ;
Belanger, Matthew J. ;
Kokkinos, Alexander ;
Koliaki, Chrysi C. ;
Mantzoros, Christos S. .
ENDOCRINE REVIEWS, 2021, 43 (03) :507-557
[5]  
[Anonymous], CARDIOVASCULAR EFFEC, DOI [10.1056/NEJMoa1212914?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub0www.ncbi.nlm.nih.gov, DOI 10.1056/NEJMOA1212914?URL_VER=Z39.88-2003&RFR_ID=ORI:RID:CROSSREF.ORG&RFR_DAT=CR_PUB0WWW.NCBI.NLM.NIH.GOV]
[6]  
[Anonymous], 2023, Pharmaceutical Technology
[7]  
[Anonymous], Lilly receives US FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
[8]  
[Anonymous], 2023, BOEHRINGER INGELHEIM
[9]  
[Anonymous], Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
[10]   Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis [J].
Anstee, Quentin M. ;
Targher, Giovanni ;
Day, Christopher P. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) :330-344
12345678910